Results 141 to 150 of about 4,101 (234)

50 | FIXED‐DURATION OUTPATIENT SUBCUTANEOUS MOSUNETUZUMAB + POLATUZUMAB VEDOTIN SHOWS ROBUST EFFICACY IN A PHASE II STUDY OF RELAPSED/REFRACTORY POST‐BTKi MANTLE CELL LYMPHOMA [PDF]

L. E. Budde, Manali Kamdar, Sarit Assouline, Nilanjan Ghosh, Seema Naik, Shazia Nakhoda, Julio C. Chávez, Thomas Ollila, Daniel J. Hodson, Dipenkumar Modi, Mariana Bastos‐Oreiro, Wahib S. Ead, Ikpesu TO, S. Pham, J. Wang, Hao Wu, Sunal Makadia, Connie Lee Batlevi, M. C. Wei, M. L. Wang   +19 more
openalex   +1 more source

P114 | FACTORS INFLUENCING THE REGIMEN CHOICE FOR FIRST-LINE THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE FIRST-CLL STUDY

Haematologica
Treatment options for patients with chronic lymphocytic leukemia (CLL) have significantly increased over the years, and different first-line chemo-free regimens are now available.
F. Perutelli, M. Arata, M.C. Montalbano, R. Minuto, M. Nicolosi, S. Pepe, M. Deodato, E. Fioribello, A. Ferrario, E. Boccellato, R. Moia, M. Bullo, D. Gottardi, M. Foglietta, C. Salvetti, R. Freilone, G. Gaidano, M. Coscia, A.M. Frustaci, F.R. Mauro, B. Bruno, C. Vitale   +21 more
doaj  

Optimizing treatment for Waldenström macroglobulinemia-associated acquired von Willebrand syndrome: a case report and literature review. [PDF]

Front Oncol
Shen K, Yang C, Ma H.
europepmc   +1 more source

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)

, 2022
J. P. Sharman, W. Jurczak, C. C. Coombs, M. Hill, D. Wang, N. C. Ku, AR Guntur, S. Shahda, C. C. Leow, P. Ghia, A. R. Mato   +10 more
openalex   +1 more source

Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL. [PDF]

Front Immunol
Wang J, Cui R, Qi Y, Mu J, Li X, Li Q, Deng Q.   +6 more
europepmc   +1 more source

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3) [PDF]

David J. Kuter, Waleed Ghanima, Nichola Cooper, Howard A. Liebman, Lei Zhang, Yu Hu, Yoshitaka Miyakawa, Luisa Elena Morales Galindo, Ana Lisa Basquiera, Chuen Wen Tan, Güray Saydam, Marie Luise Hütter‐Krönke, Chatree Chai‐Adisaksopha, David Gómez‐Almaguer, Huy Tran, Ho‐Jin Shin, Maria Cristina Pascual Izquierdo, Ilya Kirgner, Elisa Lucchini, Ganna Kuzmina, Sylvain Audia, Matias Cordoba, Remco Diab, Mengjie Yao, Michelle J. Lee, Ahmed Daak   +25 more
openalex   +1 more source

Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis. [PDF]

Oncologist
Mushtaq A, Ahmed EN, Aljumaa R, E'mar AR, Badwan O, Ashruf O, Elshaer A, Shaik A, Baroudi M, Moudgil R, Mustafa Ali MK.   +10 more
europepmc   +1 more source

Combination of Glofitamab with Pirtobrutinib in BTK Inhibitor (BTKi)-Naive or Btki-Intolerant Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium [PDF]

Madhav Seshadri, Chiung‐Yu Huang, Hildy Donner, William Pearse, Patricia A. Young, Monica Mead, Naseem Esteghamat, Christine Thacker, Lauren Nguyen, Weiyun Z. Ai, Michael A. Spinner, Lawrence D. Kaplan, Charalambos Andreadis   +12 more
openalex   +1 more source

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The Case for BTKi

, 2022
Brem, Elizabeth, O'Brien, Susan M
openaire   +2 more sources

HEMOSTATIC ALTERATIONS DURING BRUTON KINASE INHIBITORS TREATMENT

Haematologica
Patients with chronic lymphocytic leukemia (CLL) are at increased risk for major bleeding compared with the general population. The hazard ratio (HR) for major bleeding among 6,717 treated CLL/SLL patients compared with 14816 matched noncancer patients ...
M. Carpenedo
doaj